Shiny teal confetti

EKOS™ Endovascular System

The REAL-PE Analysis

The truth about EKOS™ vs. FlowTriever™ in PE interventions

The REAL-PE analysis is the largest real-world and near real-time dataset evaluating advanced therapies for PE patients.

The results?  Patients treated with the EKOS™  System had statistically significant lower rates of major bleeding and intracerebral haemorrhage than patients treated with Inari Medical’s™ FlowTriever™ system. In fact, all studied safety events trended in favor of the EKOS system, as did 30-day all-cause readmission rates.1

Hear from lead author Dr. Peter Monteleone, as he discusses the REAL-PE analysis 

In comparison to patients who were treated with the FlowTriever System, patients treated with the EKOS system had a statistically significant:

Icon of blood drop


 lower rate of major bleeding events*1
FlowTriever (n=118/682),
EKOS (n=195/1577), p=0.0018
 (ISTH Definition) 

Icon of brain hemorrhage


 lower rate of intracerebral haemorrhage(0.3% incidence of ICH in patients treated with EKOS)*1
FlowTriever (n=9/682), EKOS (n=5/1577), p=0.005

Icon of hospital

Comparable in-hospital mortality rates (p=0.167), 30-day all-cause readmission rates (p=0.777), and median lengths of hospital stay*1


Results from clinical studies are not predictive of results in other studies. Results in other studies may vary.

Product available in the European Economic Area (EEA) only. Please check availability with your local sales representative or customer service.


The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.


*Calculated from published data cited below.

1. Monteleone P, et al. Modern Treatment of Pulmonary Embolism (USCDT versus MT): Results from Real-World, Big Data Analysis (REAL-PE). Journal of the Society for Cardiovascular Angiography & Interventions; Oct 2023.

Boston Scientific provided funding to Truveta for data reporting.

All trademarks are property of their respective owners.